HCW Biologics (HCWB) Competitors $4.13 -0.11 (-2.59%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$4.50 +0.37 (+8.96%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock HCWB vs. FBLG, LGVN, ASBP, LSTA, NAII, DARE, AYTU, RVPH, CVKD, and ELEVShould you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include FibroBiologics (FBLG), Longeveron (LGVN), Aspire Biopharma (ASBP), Lisata Therapeutics (LSTA), Natural Alternatives International (NAII), Dare Bioscience (DARE), Aytu BioPharma (AYTU), Reviva Pharmaceuticals (RVPH), Cadrenal Therapeutics (CVKD), and Elevation Oncology (ELEV). These companies are all part of the "pharmaceutical products" industry. HCW Biologics vs. Its Competitors FibroBiologics Longeveron Aspire Biopharma Lisata Therapeutics Natural Alternatives International Dare Bioscience Aytu BioPharma Reviva Pharmaceuticals Cadrenal Therapeutics Elevation Oncology HCW Biologics (NASDAQ:HCWB) and FibroBiologics (NASDAQ:FBLG) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability. Do insiders & institutionals have more ownership in HCWB or FBLG? 3.0% of HCW Biologics shares are owned by institutional investors. 42.7% of HCW Biologics shares are owned by insiders. Comparatively, 20.8% of FibroBiologics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is HCWB or FBLG more profitable? FibroBiologics has a net margin of 0.00% compared to HCW Biologics' net margin of -1,712.94%. HCW Biologics' return on equity of 0.00% beat FibroBiologics' return on equity.Company Net Margins Return on Equity Return on Assets HCW Biologics-1,712.94% N/A -90.09% FibroBiologics N/A -710.25%-118.02% Which has more risk & volatility, HCWB or FBLG? HCW Biologics has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Comparatively, FibroBiologics has a beta of -0.74, indicating that its stock price is 174% less volatile than the S&P 500. Does the media refer more to HCWB or FBLG? In the previous week, FibroBiologics had 5 more articles in the media than HCW Biologics. MarketBeat recorded 5 mentions for FibroBiologics and 0 mentions for HCW Biologics. HCW Biologics' average media sentiment score of 0.00 beat FibroBiologics' score of -0.60 indicating that HCW Biologics is being referred to more favorably in the media. Company Overall Sentiment HCW Biologics Neutral FibroBiologics Negative Which has preferable earnings and valuation, HCWB or FBLG? FibroBiologics has lower revenue, but higher earnings than HCW Biologics. FibroBiologics is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHCW Biologics$2.57M2.31-$30.02M-$23.25-0.18FibroBiologicsN/AN/A-$11.16M-$0.36-1.80 Do analysts recommend HCWB or FBLG? HCW Biologics currently has a consensus target price of $35.00, suggesting a potential upside of 747.46%. FibroBiologics has a consensus target price of $13.00, suggesting a potential upside of 1,904.32%. Given FibroBiologics' stronger consensus rating and higher possible upside, analysts plainly believe FibroBiologics is more favorable than HCW Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HCW Biologics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroBiologics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryHCW Biologics and FibroBiologics tied by winning 8 of the 16 factors compared between the two stocks. Get HCW Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HCWB vs. The Competition Export to ExcelMetricHCW BiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.95M$3.02B$5.52B$9.35BDividend YieldN/A2.45%4.74%4.14%P/E Ratio-0.1817.8529.0523.78Price / Sales2.31318.52444.6497.50Price / CashN/A40.5624.4827.20Price / Book-0.688.488.365.61Net Income-$30.02M-$54.98M$3.25B$265.26M7 Day Performance-0.48%-3.52%-3.57%-4.34%1 Month Performance-1.20%15.65%5.10%4.11%1 Year Performance-82.93%6.51%25.36%17.92% HCW Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HCWBHCW Biologics2.6836 of 5 stars$4.13-2.6%$35.00+747.5%-82.9%$5.95M$2.57M-0.1840Gap DownFBLGFibroBiologics3.1733 of 5 stars$0.62-6.3%$13.00+2,013.8%-86.7%$24.40MN/A-2.9310Earnings ReportUpcoming EarningsHigh Trading VolumeLGVNLongeveron2.2794 of 5 stars$1.58-3.9%$8.67+449.9%-43.4%$23.59M$2.23M-0.2520Negative NewsShort Interest ↑Gap DownASBPAspire BiopharmaN/A$0.47-2.1%N/AN/A$23.33MN/A0.00N/ALSTALisata Therapeutics2.2998 of 5 stars$2.64+0.5%$23.50+788.8%-22.6%$22.71M$1M-1.1530Positive NewsUpcoming EarningsNAIINatural Alternatives InternationalN/A$3.65+1.4%N/A-33.5%$22.56M$113.80M-2.63290Positive NewsDAREDare Bioscience1.7408 of 5 stars$2.48-2.9%$12.00+384.8%-27.1%$22.35M$10K-14.5630Upcoming EarningsShort Interest ↑AYTUAytu BioPharma3.1565 of 5 stars$2.52-4.4%$10.00+297.6%-4.8%$22.32M$81M-3.45160RVPHReviva Pharmaceuticals2.8413 of 5 stars$0.46-5.9%$9.00+1,852.3%-56.9%$22.13MN/A-0.585Short Interest ↑High Trading VolumeCVKDCadrenal Therapeutics2.133 of 5 stars$11.00-5.0%$32.00+190.9%N/A$21.74MN/A-1.194Positive NewsUpcoming EarningsGap UpELEVElevation Oncology2.1198 of 5 stars$0.37flat$3.39+827.6%N/A$21.62MN/A-0.4540Upcoming Earnings Related Companies and Tools Related Companies FibroBiologics Competitors Longeveron Competitors Aspire Biopharma Competitors Lisata Therapeutics Competitors Natural Alternatives International Competitors Dare Bioscience Competitors Aytu BioPharma Competitors Reviva Pharmaceuticals Competitors Cadrenal Therapeutics Competitors Elevation Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HCWB) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWall Street Laughed. Now They're Buying.For six months, I’ve been pounding the table on a major gold miner—while Twitter pundits laughed. But now, the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Create New Advertiser | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HCW Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share HCW Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
